The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Thu, 22nd Oct 2020 11:06

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 250 - LOSERS

----------

Shaftesbury, down 13%, and Capital & Counties, down 11%. Shaftesbury said it intends to raise GBP307 million via the issue of new shares to ensure financial flexibility to navigate the "unprecedented" challenges created by the Covid-19 pandemic. Current market capitalisation is GBP1.33 billion. Capital & Counties Properties said it will participate in the Shaftesbury fundraise by providing GBP65 million.

----------

Moneysupermarket, down 5.7%, the price comparison website firm said revenue dropped across all of its businesses in the third quarter, with the company blaming the "disruption" caused by the pandemic. In the three months to September 30, Moneysupermarket's total revenue dropped 16% year on year to GBP85.1 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Premier African Minerals up 19%. The southern Africa-focused miner said it has settled all amounts it owes to directors, employees and other creditors, amounting to GBP600,057 of shares. Along with the GBP1.1 million placing, completed on Wednesday, the company is now debt free.

----------

OPG Power Ventures, up 16%. The Indian power plant operator said revenue in the year ended March 31 rose 9.5% to GBP154.0 million from GBP140.6 million. Pretax profit slipped 14% to GBP14.5 million from GBP16.9 million.

----------

4D Pharma up 16% after it proposed a merger with special-purpose acquisition company Longevity Acquisition Corp. Longevity shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each - an 18% premium to its GBP0.932 closing price on Wednesday - GBP144.5 million altogether. 4D's current market capitalisation is GBP141.1 million. The enlarged company will also launch an American depositary receipts programme, eyeing a Nasdaq listing.

----------

Pendragon up 12%, the motor retailer said it delivered a "very strong" third quarter, with total revenue down 14% annually, but up 1.2% like-for-like. Underlying pretax profit surged to GBP27.3 million from GBP3.0 million a year earlier. Opts not to reinstate annual guidance, however.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Kibo Energy, down 12% after the Africa-focused energy firm posted a narrowed loss in the six months to June 30. Its pretax loss slimmed to GBP1.3 million from GBP1.8 million, though like last year, it generated no revenue. Noted that Covid-19 has caused delays to its project development targets.

----------

Thalassa Holdings, dropped 12% after a regulatory filing showed investor Lombard Odier Asset Management Ltd trimmed its stake in the British Virgin Islands-based investment holding company to 1.4% from 14% during a transaction on Wednesday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Jan 2020 08:42

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

Read more
6 Nov 2019 11:00

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Read more
6 Nov 2019 09:36

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

Read more
5 Nov 2019 15:13

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

Read more
8 Oct 2019 10:35

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

Read more
8 Oct 2019 09:14

4d Pharma And Merck To Collaborate On Gut Disease Treatments

4d Pharma And Merck To Collaborate On Gut Disease Treatments

Read more
8 Oct 2019 08:30

4D Pharma inks research collaboration agreement with Merck & Co

(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.

Read more
30 Sep 2019 09:33

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

Read more
27 Aug 2019 16:45

4D Pharma Appoints Sangamo Therapeutics Boss Macrae To Board

(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.Macrae currently serves as president & of

Read more
25 Jul 2019 11:26

4d Pharma Picks New Candidate; Encouraging Data On Lead Biotherapeutic

(Alliance News) - 4d Pharma PLC on Thursday announced positive preclinical data on lead biotherapeutic candidate MRx0518 and the identification of a new candidate as well.The new candidate,

Read more
8 Jul 2019 09:29

4d Pharma Begins Live Biotherapeutics Asthma Programme

(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.The double-blind, placebo-controlled study will enrol 90

Read more
13 Jun 2019 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Friday 14 JuneMP Evans GroupSerabi GoldMonday 17 JuneChallenger 18

Read more
30 May 2019 14:26

DIRECTOR DEALINGS: 4d Pharma Chair Buys GBP15,000 In Shares

LONDON (Alliance News) - 4d Pharma PLC on Thursday said that Chair David Norwood acquired 15,000 shares in the company.On Wednesday, Norwood bought the shares at 100.00 pence each for a of

Read more
21 May 2019 11:27

4D Pharma losses widen as it spends cash on development activities

(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.

Read more
21 May 2019 10:29

4d Pharma Annual Loss Widens On Live Biotherapeutic Development Costs

LONDON (Alliance News) - 4d Pharma PLC on Tuesday said its loss widened in 2018 on research and development costs as it continued to develop its live biotherapeutic products, which contain living

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.